Legal Notices
Legal Notices
Search
Legal & Compliance
Legal & Compliance
legal_notices_bicl_website_en
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
PIPEDA Terms of Use Consent - Contact us form - english
PIPEDA Terms of Use Consent - Contact us form - english
Terms Of Use
TERMS OF USE
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Osteoarthritis in dogs: Protecting your pet from pain
Osteoarthritis in dogs: Protecting your pet from pain
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Accessibility Plan
Accessibility Plan
Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Accessible Customer Service Policy
Accessible Customer Service Policy
Hannah Bussmann
Hannah Bussmann speaks about working in Global Internal Investigations as part of corporate legal and compliance at Boehringer Ingelheim.
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Rafał Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis